Targeting Systems || About Us

About Us > Advisory Board

Advisory Board

Gregory D. Williams | Strategic Alliance :

We are honored to have Greg on our advisory board. With over 28 years of experience in all aspects of worldwide IP acquisition and management, we feel privileged to have him advise us on our business deals and evaluate our rapidly expanding IP portfolio. His expertise includes patenting, trademark, technology transfer and alliance negotiation, global business development and strategic counseling for all departments including the senior management and CEOs. During his 26 year tenure (both as outside and as their General Counsel) at New England Biolabs (a leading Life Science Company located in Ipswich MA), Greg established and managed the licensing/legal department of the company with 130 issued patents. He also served on the Board of the Boston Patent Law Association from 1989-1997 and as its President in 1996.

He is a selectman in his home town of South Hampton New Hampshire and on the fun side he enjoys skiing, golf, boating and horsebackriding. He also served for several years on the advisory board of two non-profits, (http://artsbridgeinstitute.org/) and Save one Life (http://www.saveonelife.net/)

Greg's CV read more..

Dr. Philip H. Schwartz | Stem Cell research :

Trained at UCLA‘s Brain Research Institute, Dr. Schwartz is a full-time stem cell biologist and holds a Senior Scientist position at the Children‘s Hospital of Orange County (CHOC) Research Institute. Dr. Schwartz is Director and Founder of CHOC's National Human Neural Stem Cell Resource (NHNSCR), an Associate Research Biologist at the University of California, Irvine (UCI), Developmental Biology Center, and a Visiting Associate Professor in the Stem Cells and Regeneration Program of the Burnham Institute.

A Principal Investigator of one of the NIH‘s 5 T15 Human Embryonic Stem Cell Culture Training Courses, Dr. Schwartz trains national and international scientists in current human embryonic and neural stem cell techniques. Dr. Schwartz regularly participates in special study sections on stem cells at the NIH. As part of the NHNSCR, Dr. Schwartz maintains clinical collaborations with several west Coast university hospitals and has active research collaborations with over 30 national and international stem cell researchers. Dr. Schwartz also regularly disseminates stem cell research information to the lay public by way of the print, television, and radio media. Dr. Schwartz‘ current organizational efforts have been to establish the Center for Stem Cell Transplantation at CHOC and the Stem Cell Research Center at UCI, in addition to fostering formal collaborative efforts between CHOC and UCI in stem cell research. Dr. Schwartz sits on the CHOC Ethics Committee and IACUC and is currently funded by the CHOC Foundation for Children and by the National Institutes of Health.

Ms. Connie Kohne | Clinical Research and Diagnostics :

Some of the research at Targeting Systems has clinical and diagnostic applications. We are lucky to have on our advisory board Ms. Kohne iwho has over twenty years of broad-based experience in regulatory affairs, clinical affairs, quality assurance, quality control, environmental and safety administration for the pharmaceutical, biopharmaceutical and medical device industries.

Ms. Kohne served as the Mayor of Lowell, Oregon, from 1981 to 1984. After 1984, she worked at Scripps Research Clinic as a peptide chemist and then for Gen-Probe as a quality assurance, quality control, clinical and regulatory affairs professional, where she obtained multiple 510K approvals from the FDA for nucleic acid medical diagnostic devices for infectious disease. Ms. Kohne worked in the area of gene therapy from 1994 to 1996 as the Director of Regulatory Affairs at Canji Inc., a subsidiary of Schering-Plough Corporation, working on cancer applications using an adenoviral P53 gene and other gene constructs. From 1996 thru 1999, Ms. Kohne worked at Agouron Pharmaceuticals Inc, purchased by Pfizer, as the Director of Regulatory Affairs, Head of Virology, Advertising and Promotion Regulatory Affairs.

During her tenure at Agouron Pharmaceutifuls, she was responsible for a variety of small molecule antiviral drugs in all phases of clinical development and was a key member of the team that submitted and obtained approval for Viracept (nelfinavir mesylate) an HIV protease inhibitor for both adults and children. Ms. Kohne‘s work with the FDA in the grassroots initiative was recognized by the Commissioner of the Food and Drug Administration by receiving the Commissioner‘s Special Citation in 1998 and then by the Vice President of the United States for outstanding leadership in furthering the FDA‘s goals of public health with a Hammer Award in 1997. From 2000 to 2002, Ms. Kohne worked in at Gen-Star Corporation, as the Vice President of Regulatory Affairs and Corporate Quality, working with various gene constructs including a minimized adenoviral vector containing the full length Factor VIII gene for application in the treatment of Hemophilia A. Ms. Kohne founded Jaden Bioscience Inc. with Dr. David Kohne (Scientific founder of Genprobe Inc) in 2005 and is serving as the President and CEO.